Quality of drug label information on QT interval prolongation

International Journal of Risk and Safety in Medicine

Volumn 26, Issue 2, 2014, Pages 89-98

  Warnier, Miriam J ^a,b   Holtkamp, Frank A ^c,d   Rutten, Frans H ^b   Hoes, Arno W ^b   De Boer, Anthonius ^a   Mol, Peter G M ^c,d   De Bruin, Marie L ^a,c,e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cardiovascular agents adverse effects; communication; drug approval; drug labeling legislation jurisprudence; torsades de pointes chemically induced

Indexed keywords

ORPHAN DRUG;

ARTICLE; DRUG INFORMATION; DRUG LABELING; HEALTH CARE PERSONNEL; HUMAN; QT INTERVAL; QT PROLONGATION; RISK FACTOR; ADVERSE DRUG REACTION; ATTITUDE TO HEALTH; CHEMICALLY INDUCED; ELECTROCARDIOGRAPHY; EUROPE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION SYSTEM; PATIENT EDUCATION; RISK ASSESSMENT; STANDARDS;

ARRHYTHMIAS, CARDIAC; DRUG LABELING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTROCARDIOGRAPHY; EUROPE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEART CONDUCTION SYSTEM; HUMANS; PATIENT EDUCATION AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84902294782     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-140612     Document Type: Article

References (15)

1. Cubeddu L. QT prolongation and fatal arrhythmias: A review of clinical implications and effects of drugs. Am J Ther. 2003;10:452-7.
2. Kramer D, Zimetbaum P. Long-QT syndrome. Cardiol Rev. 2011;19:217-25.
3. Stockbridge N, Morganroth J, Shah RR, et al. Dealing with global safety issues: Was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf. 2013;36:167-82.
4. Mol PG, Straus SM, Piening S, et al. A decade of safety-related regulatory action in the Netherlands: A retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf. 2010;33:463-74.
5. Guidance for Industry, E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005;Available at: http://www.fda.gov/downloads/Regulatory Information/ Guidances/ucm12 9357.pdf. Accessed March, 2013.
6. Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonarrhythmic drugs (CHMP/ICH/2/04). 2005; Available at: http://ec.europa.eu/health/files/eudralex/ vol-2/c/smpc guideline rev2 en.pdf. Accessed March, 2013.
7. A guideline on summary of product characteristics (SmPC). 2009; Available at: http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc guideline rev2 en.pdf. Accessed March, 2013.
8. Why look at an SPC? Drug Ther Bull. 2009;47:56-8.
9. European Medicines Agency database of European public assessment reports. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ landing/epar search.jsp. Accessed March, 2013.
10. Markovaara J, Oxlade N, Williams R. Scrip's pharmaceutical company league tables 2008. http://www scripnews com/multimedia/archive/00042/Scrip League Tables 42249a xls, accessed on March 2013.
11. Putzeist M, Mantel-Teeuwisse AK, Gispen-De Wied CC, et al. Regulatory scientific advice in drug development: Does company size make a difference? Eur J Clin Pharmacol. 2011;67:157-64.
12. Al-Khatib SM, Allen La Pointe NM, Kramer JM, et al. A survey of health care practitioners' knowledge of the QT interval. J Gen Intern Med. 2005;20:392-6.
13. Bastholm Rahmner P, Andersen-Karlsson E, Arnhjort T, et al. Physicians' perceptions of possibilities and obstacles prior to implementing a computerised drug prescribing support system. Int J Health Care Qual Assur Inc Leadersh Health Serv. 2004;17:173-9.
14. Rubrichi S, Quaglini S. Summary of Product Characteristics content extraction for a safe drugs usage. J Biomed Inform. 2012;45:231-9.
15. Rubrichi S, Quaglini S, Spengler A, et al. A system for the extraction and representation of summary of product characteristics content. Artif Intell Med. 2013;57:145-54.